HC Wainwright Cuts Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $510.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target cut by HC Wainwright from $570.00 to $510.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on ALNY. JPMorgan Chase & Co. lowered their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 10th. Raymond James Financial restated an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Wells Fargo & Company reduced their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 20th. Finally, Bank of America cut their price target on shares of Alnylam Pharmaceuticals from $529.00 to $462.00 and set a “buy” rating on the stock in a research report on Friday. Twenty-two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $477.13.

Alnylam Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ:ALNY opened at $338.06 on Friday. The firm has a market cap of $44.66 billion, a P/E ratio of 1,408.58 and a beta of 0.35. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The business has a fifty day simple moving average of $399.61 and a 200 day simple moving average of $425.13. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 12,128 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $9,615,155.52. The trade was a 36.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Pushkal Garg sold 1,510 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the completion of the sale, the executive vice president directly owned 22,511 shares of the company’s stock, valued at approximately $8,168,566.57. This trade represents a 6.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 56,955 shares of company stock valued at $24,072,733 over the last three months. 1.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $25,000. Salomon & Ludwin LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $27,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $29,000. Ameriflex Group Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $32,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $36,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Barclays initiated coverage with an overweight (positive) recommendation — new institutional attention and an overweight start can attract buyers and support the share price. Barclays Initiates Coverage on Alnylam
• Positive Sentiment: Bank of America lowered its price target from $529 to $462 but maintained a Buy rating (implies ~36.7% upside vs. current price), which is supportive versus a full downgrade. BofA PT cut to $462
• Positive Sentiment: HC Wainwright cut its target from $570 to $510 but kept a Buy rating (implies ~50.9% upside), another vote of confidence from a sell-side firm. HC Wainwright PT cut to $510
• Positive Sentiment: Alnylam outlined a new five‑year strategy, “Alnylam 2030,” and is projecting ~ $5.3B revenue for 2026 — strategic growth targets and a multi‑year plan can support investor confidence in long‑term upside. Alnylam projects 2026 revenue ~$5.3B
• Neutral Sentiment: Alnylam will webcast a conference call to discuss Q4 and full‑year 2025 results — standard corporate event that may move the stock depending on actual results and guidance. Webcast of Q4/FY2025 results
• Neutral Sentiment: Reported short‑interest data shows effectively zero reported short position (data appears inconsistent/placeholder); this item is unlikely to explain intraday moves. (Internal short‑interest report)
• Negative Sentiment: Morgan Stanley lowered its price target from $495 to $408 and moved to an Equal Weight rating — a visible downgrade in sentiment from a major bank which likely pressured the stock. Morgan Stanley PT cut to $408
• Negative Sentiment: Technical context: the stock is trading below both its 50‑day (~$401.57) and 200‑day (~$423.47) moving averages, which can amplify downside as trend‑following and momentum flows react.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.